ABBOTT LABORATORIES vs ELI LILLY AND COMPANY, two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where ABT and LLY diverge most: on ev/ebitda, ABT reads 18.5 and LLY reads 550.3; on p/b, ABT reads 3.30 and LLY reads 32.74. The rest of the comparable metrics sit closer together. On valuation, today's ABT price has a different growth bar priced in than LLY (+8.8% implied for ABT vs +22.2% for LLY); the higher figure is the steeper assumption to clear, not a better or worse stock. What ABT's price implies is a bet that sits within the historical range (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | ABT | LLY |
|---|---|---|
| Price | $99.62 | $1178.18 |
| Market cap | $174.0B | $1.11T |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | +8.8% | +22.2% |
| P/E | 27.9 | 39.5 |
| P/B | 3.30 | 32.74 |
| P/S | 3.86 | 13.92 |
| EV/EBITDA | 18.5 | 550.3 |
| Revenue growth | +6.6% | +49.9% |
| Operating margin | 12.1% | — |
| Net margin | 13.9% | 33.5% |
| Return on equity | 11.9% | 78.8% |
| Return on assets | 5.7% | 18.8% |
| Return on invested capital | 6.6% | 1.4% |
| FCF yield | 4.2% | 1.6% |
| Dividend yield | 2.4% | 0.5% |
| Debt / equity | 0.65 | 1.62 |
| Current ratio | 1.39 | 1.35 |
| Altman Z (solvency) | 7.16 | 7.02 |
| Piotroski F (quality) | 6 / 9 | 7 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.